Document:

Prepared by MerrillDirect

Exhibit 10.23

[ * ] = Certain
confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

May
18, 2001

Biosearch Italia, S.p.A.

Via Lepetit, 34

21040 Gerenzano

Italy

Re:  License and Supply Agreement between
IntraBiotics Pharmaceuticals, Inc. (“IntraBiotics”) and Biosearch Italia,
S.p.A. (“Biosearch”) dated as of May 8, 1998 (the “Agreement”)

Ladies
and Gentlemen:

In
May 1998, IntraBiotics and Biosearch entered into the Agreement to permit
IntraBiotics to develop and commercialize, in the United States and Canada,
formulations other than [*] formulations of Biosearch’s proprietary compound,
Ramoplanin, for the treatment or prevention of infectious diseases and
conditions in humans.  Since that time,
IntraBiotics has worked for the Development of Licensed Products, including commencing
clinical trials for oral Ramoplanin as a treatment for vancomycin resistant Enterococcus
faecium (“VRE”). 
IntraBiotics has now determined that because of limited cash resources
and higher than expected program expenses, IntraBiotics must terminate such
trials immediately to conserve resources. Accordingly, Biosearch intends to
reacquire, at the terms specified hereinbelow, the rights in and to the
Licensed Compound and/or Licensed Products granted to IntraBiotics under the
Agreement.  The foregoing
notwithstanding, IntraBiotics shall, for a certain transition period, continue
the development of Ramoplanin in order to avoid any interruption of the related
activities and enable Biosearch to continue and complete under its control the
Development and Commercialization contemplated in the Agreement; and in this
perspective Biosearch is ready to advance to IntraBiotics the related necessary
costs. Accordingly, IntraBiotics and Biosearch hereby agree to amend the
Agreement as follows:

	1.	Definitions. Unless otherwise expressly provided herein, defined
  terms used in this Amendment shall have the same meaning as set forth in the
  Agreement, and all terms herein shall be incorporated into the Agreement.
	 	 
	2.	The following new Article 15 Transition Period  shall
  be added to the agreement as follows:

“15.1  Reacquisition of Licensed Products.
The Parties hereby acknowledge and agree that effective upon expiration of the
Transition Period (as hereinafter defined) IntraBiotics’ rights under Sections
5.1 and 5.3 of the Agreement with respect to Licensed Products (but not Topical
Products) shall be terminated and will revert to Biosearch, subject to
IntraBiotics’ option rights under Section 15.6.  Thereafter, Biosearch will have the right to conduct Development
and Commercialization of Licensed Products (but not Topical Products) subject
to a royalty obligation to IntraBiotics as set forth in Section 15.9.  During the period [*], IntraBiotics will
retain the rights and licenses granted it under Sections 5.1 and 5.3 of the
Agreement to conduct Development and Commercialization of Topical Products,
subject to Sections 15.6 and 15.8.2.

15.2  Transition Period.  Effective
June 1, 2001 through and including August 31, 2001, (the “Transition Period”),
Biosearch shall be responsible for paying [*] incurred by IntraBiotics’ in
connection with Development of Licensed Products for treatment of vancomycin
resistant Enterococcus
faecium (“VRE”) in humans as set forth in Article 2 of the Agreement
during the Transition Period.  Appendix
A attached hereto sets forth a description of the specific activities to be
paid for by Biosearch.  IntraBiotics
will continue to perform such Development activities with respect to treatment
of VRE during the Transition Period, or any extension thereof, so as to avoid
any interruption of the activities undertaken and enable continuation of the
Development thereafter by or under the control of Biosearch or its licensees,
aimed at achieving the milestones contemplated in Section 4.2 for Licensed
Products for treatment of VRE.

15.3     Action during Transition Period.
During the Transition Period or any mutually agreed extension thereof,
IntraBiotics will undertake such actions as are reasonable and necessary in
order to enable it, upon expiration of the Transition Period, to (i) complete
transfer to Biosearch of responsibility for conducting the Development and
Commercialization of Licensed Products (but not Topical Products); (ii) provide
all Information regarding its Development of Licensed Products, or which is
necessary to obtain Regulatory Approval of such Licensed Products in the
Territory, not already provided to Biosearch pursuant to Section 2.2(c) of the
Agreement; and (iii) assign to Biosearch as of the date of such expiration all
right, title and interest in and to any regulatory filings in the Territory
pertaining to Licensed Products (but not Topical Products).  Biosearch will be responsible for [*]
incurred by IntraBiotics in connection with the transition activities described
in (i)-(iii) above. Should the transfer procedure indicated above not be
completed by August 31, 2001, the two parties shall mutually agree on the
appropriate extension to enable completion, and update Appendix A accordingly.

15.4     Development Expense Reports.  IntraBiotics will provide to Biosearch [*]
reports of expenses incurred in connection with IntraBiotics’ Development and
transition activities under Section 15.2 and 15.3.  Such reports will be provided [*] after [*] to which the report
pertains.  IntraBiotics will allow one
or more persons designated by Biosearch to monitor the progress of the
Development activities and to have reasonable access to the facilities of
IntraBiotics, during normal business hours and upon reasonable advance notice,
accordingly.

15.5     IntraBiotics’ Option to Reacquire Rights to Licensed Product.   During the period from [*], IntraBiotics
will have an exclusive option to reacquire the right to conduct the Development
and Commercialization of Licensed Products in the Territory and in the Field
(the “Reacquisition Option”).  IntraBiotics
may exercise the Reacquisition Option by notifying BioSearch in writing of such
exercise not later than [*], and delivering to Biosearch (i) [*]; and (ii)
written objective evidence that either (a) [*] or (b) [*]. As consideration for
the Reacquisition Option, IntraBiotics will pay to Biosearch, concurrent with
IntraBiotics’ exercise of its Reacquisition Option, [*].  Upon IntraBiotics’ timely exercise of its
Reacquisition Option, Sections 15.6, 15.7 and 15.8 shall be of no further force
or effect.  All materials disclosed to
Biosearch in connection with IntraBiotics’ exercise of its option hereunder
shall be subject to the confidentiality provisions of Section 9.

15.6     IntraBiotics’ Rights to Topical Product.  Commencing
on the expiration of the Transition Period, IntraBiotics’ rights under Sections
5.1 and 5.3 and obligations under this Agreement to conduct Development and
Commercialization of Licensed Products shall apply only to Topical Products in
the Territory and in the Field.  If
IntraBiotics timely exercises its Reacquisition Option as set forth in Section
15.5, or commences clinical development activity with respect to [*], then
IntraBiotics will retain its right to develop Topical Products until the
expiration or earlier termination of this Agreement pursuant to Section
11.  If IntraBiotics does not timely
exercise its Reacquisition Option, and does not start any clinical development
activity for Topical Products by [*], then all rights in and to Topical
Products shall revert to Biosearch effective [*], and IntraBiotics shall have
no rights to make, have made, use, import, offer, sell, offer for sale and have
sold Licensed Products in the Field and in the Territory.  The foregoing notwithstanding, IntraBiotics
shall be entitled to extend the expiration of the term specified herein from
[*] provided it has given, prior to [*].

15.7     Effect of Expiration of the Transition Period.  Upon expiration of the Transition Period, or
any extension thereof, all rights in and to Licensed Products other than Topical
Products shall revert to Biosearch effective upon such expiration, and
IntraBiotics shall have no rights to make, have made, use, import, offer, sell,
offer for sale and have sold Licensed Products other than Topical Products in
the Field and in the Territory, subject to IntraBiotics’ option rights under
Section 15.5.

15.8     Effect of Termination of IntraBiotics’ Development and
Commercialization Rights and Obligations.

15.8.1  Upon expiration of the
Transition Period, or any extension thereof, and if IntraBiotics does not
timely exercise its Reacquisition Option:

15.8.1.1            all rights and licenses
granted to IntraBiotics under Article 5 with respect to Licensed Product other
than Topical Product shall terminate and revert to Biosearch, and Biosearch’s
obligations under Section 3.1(a) of the Agreement shall terminate and be of no
further force or effect;

15.8.1.2            IntraBiotics shall, at
Biosearch’s request, return to Biosearch or destroy all Biosearch Information
and any other Confidential Information relating to such Licensed Product other
than Topical Product, and any Bulk Licensed Compound supplied by Biosearch for
clinical development or commercial distribution of such Licensed Product other
than Topical Product;

15.8.1.3            IntraBiotics shall have
no further rights or obligations under this Agreement to conduct Development or
Commercialization activities or to manufacture Licensed Compound for Licensed
Product other than Topical Product in the Field and in the Territory;

15.8.1.4            IntraBiotics shall have
no further obligation to make milestone payments with respect to Licensed
Products that are not Topical Products under Section 4.2 of this Agreement that
are not due and payable as of the expiration of the Transition Period, or any
extension thereof;

15.8.1.5            Biosearch shall have no
obligation to manufacture and supply Bulk Licensed Compounds for Licensed
Product other than Topical Product to IntraBiotics in the Field and in the
Territory.

             15.8.2  Thereafter, if
IntraBiotics does not commence clinical development of [*], then:

15.8.2.1            all rights and licenses
granted to IntraBiotics under Article 5 with respect to Topical Information
relating to such Topical Product, and any Bulk Licensed Compound supplied by
Biosearch for clinical development or commercial distribution of such Topical
Product;

15.8.2.2            IntraBiotics shall have
no further rights or obligations under the Agreement to conduct Development or
Commercialization activities or to manufacture Licensed Compound for Topical
Product in the Field and in the Territory;

15.8.2.3            IntraBiotics shall have
no further obligation to make milestone payments under Section 4.2 of this
Agreement with respect to Topical Products that are not due and payable as of
the expiration of the Transition Period;

15.8.2.4            Biosearch shall have no
obligation to manufacture and supply Bulk Licensed Compounds for Topical
Product to IntraBiotics in the Field and in the Territory;

15.9     Compensation.  In consideration for the Development work
performed by IntraBiotics with respect to Licensed Products in the Field,
Biosearch shall pay to IntraBiotics (a) starting from the execution of this
Amendment, [*], the corresponding amounts for such months calculated according
to Appendix A attached hereto, [*] upon which IntraBiotics will draw to fund
the Development work for the ongoing VRE BSI prevention Phase III trial; (b)
[*]; and (c) upon Commercialization of Licensed Product other than Topical
Product [*], royalties [*] of Biosearch’s Net Sales of such Licensed Product
[*], until the later of (x) the date upon which the last to expire of the
Biosearch Patents and IntraBiotics Patents covering the manufacture, use, sale,
offer for sale or import of such Licensed Product in such country expires, or
(y) [*] after first commercial sale of such Licensed Product in such
country.  If, upon completion of all
transition activities required to be performed under Section 15.3, [*],
IntraBiotics will [*].  For the purposes
hereof, “Biosearch Net Sales” shall mean the amount invoiced for sales of a
Licensed Product other than a Topical Product in final dosage form by
Biosearch, its Affiliates or its licensees to a Third Party end user, less (i)
discounts, including cash discounts, or rebates (including government-mandated
rebates), retroactive price reductions or allowances actually allowed or
granted from the billed amount, (ii) credits or allowances actually granted
upon claims, rejections or returns of such Licensed Products, including
recalls, (iii) freight, postage, shipping and insurance charges paid for
delivery of such Licensed Product, to the extent billed, and (iv) taxes, duties
or other governmental charges levied on or measured by the billing amount when
included in billing, as adjusted for rebates and refunds. The provisions of
Sections 8.4(b) – 8.8 shall apply to Biosearch with respect to any amounts
payable by Biosearch.

3.          A new Section 1.33 shall be added as
follows:

1.33  “Topical Product” means
any product including or incorporating the Licensed Compound in a form or
formulation suitable solely for topical and external use (such as gel, creams,
sprays, and the like), including product delivered transdermally.

 

	4.	Effective as from the expiration of the
  Transition Period or any extension thereof and provided that IntraBiotics
  does not exercise its option pursuant to Section 15.5, Section 1.10 shall be
  deleted in its entirety and shall be replaced with the following:

“1.10 “Excluded Formulations”
means any formulation of the Licensed Compound except those suitable solely for
topical and external use (such as gel, creams, sprays, and the like).

	5.	Section 11.4 shall be deleted in its
  entirety and shall be replaced with the following:

             11.4     Effect of Termination

                           (a)         Upon termination of
this Agreement by BioSearch for IntraBiotics’ material breach pursuant to
Section 11.2 or by IntraBiotics pursuant to Section 11.3, [which termination
occurs while IntraBiotics is developing or commercializing a Licensed Product,
all rights and licenses granted to IntraBiotics with respect to the Licensed
Product under Article 5 shall terminate. 
Furthermore, upon termination by BioSearch pursuant to Section 11.2 or
by IntraBiotics pursuant to Section 11.3 at any time, IntraBiotics shall pay
all sums accrued hereunder which are then due (except as expressly otherwise
provided in this Agreement), and IntraBiotics shall promptly assign to
BioSearch all right, title and interest in and to any regulatory filings in the
Territory pertaining to Licensed Products and shall deliver to BioSearch any
IntraBiotics Information necessary to obtain the Regulatory Approval of
Licensed Products in the Territory which has not been obtained as of the date
of termination.  If this Agreement is
terminated by BioSearch pursuant to Section 11.2 or by IntraBiotics pursuant to
Section 11.3 at any time, IntraBiotics shall return to BioSearch, or at
BioSearch’s request destroy, all BioSearch Information and any other
Confidential Information relating to the Licensed Compound or Licensed
Products, and any Bulk Licensed Compound supplied by BioSearch for clinical
development or commercial distribution.

                          (b)
Upon termination of this Agreement by IntraBiotics for BioSearch’s
material breach pursuant to Section 11.2, which termination occurs while
IntraBiotics is developing or commercializing a Licensed Product, all licenses
granted to IntraBiotics shall survive, subject to the payment of a royalty to
BioSearch equal to [*] of Licensed Products by BioSearch, its Affiliates or
sublicensees, [*].  The provisions of
Sections 8.4 through 8.8 shall apply with respect to any such royalties payable
under this Section 11.4(b).  If
BioSearch is manufacturing Licensed Bulk Compound at the time of any
termination by IntraBiotics of this Agreement for BioSearch’s material breach,
BioSearch shall continue to provide for manufacture of Bulk Licensed Compound
to the extent provided prior to notice of such termination until such time as
IntraBiotics is able to secure an equivalent alternative commercial
manufacturing source for the Territory, as requested by IntraBiotics; provided,
however, that IntraBiotics shall pay to BioSearch [*] plus an
additional [*] thereof.  Further, upon
IntraBiotics’ request, BioSearch shall provide such technical assistance as
needed by IntraBiotics to commence manufacture of Bulk Licensed Compound, at
[*].

	6.	If IntraBiotics does not [*], and does
  not [*] by [*], then Sections  10.2,
  10.5, 10.6, 10.7 and 10.8 shall expire and shall be of no further force or
  effect.

7.          The following new Section 13.4 shall
be inserted after Section 13.3:

13.4  Indemnification after the Transition
Period.  Upon
expiration of the Transition Period, or any extension thereof, then with
respect to Licensed Products to which Biosearch has reacquired the right to
make, have made, use import, sell, offer, offer for sale and have sold in the
Field and in the Territory, the following indemnification provisions shall
apply:

             (a) Indemnification by Biosearch.  Biosearch hereby agrees to indemnify, hold
harmless and defend IntraBiotics against any and all expenses, costs of defense
(including without limitation attorneys’ fees, witness fees, damages,
judgments, fines and amounts paid in settlement) and any amounts IntraBiotics
becomes legally obligated to pay because of any Third Party claim or claims
against it to the extent that such claim or claims result from (i) Biosearch’s
negligence, (ii) Biosearch’s breach or alleged breach of any representation or
warranty by Biosearch or of any other provision of the Agreement, or (iii) the
possession, manufacture, use, handling, storage, sale, administration or other
disposition of Bulk Licensed Compound or of products containing the Licensed
Compound by Biosearch, its agents or licensees or sublicensees (other than
IntraBiotics), except to the extent such claim or claims arise from the
negligence, recklessness or willful misconduct of IntraBiotics or any breach of
any representation or warranty of IntraBiotics made pursuant to Section 12 of
the Agreement; provided that IntraBiotics provides Biosearch with prompt notice
of any such claim and the exclusive ability to defend (with the reasonable
cooperation of IntraBiotics) and settle any such claim.

             (b)
Indemnification by IntraBiotics.  IntraBiotics hereby agrees to indemnify, hold
harmless and defend Biosearch against any and all expenses, costs of defense
(including without limitation attorneys’ fees, witness fees, damages,
judgments, fines and amounts paid in settlement) and any amounts Biosearch
becomes legally obligated to pay because of any Third Party claim or claims
against it to the extent that such claim or claims arise out of (i)
IntraBiotics’ negligence, recklessness or willful misconduct or (ii)
IntraBiotics’ breach or alleged breach of any representation or warranty by
IntraBiotics or of any other provision of the Agreement; provided that
Biosearch provides IntraBiotics with prompt notice of any such claim and the
exclusive ability to defend (with the reasonable cooperation of Biosearch) or
settle any such claim, and provided further that such indemnities shall not
apply to losses resulting from Biosearch matters covered under Section 13.1
above.

             (c) Mechanics. The provisions of
Section 13.3 of the Agreement shall apply in the event the Parties cannot agree
as to the identification of any particular loss or claim.

8.          IntraBiotics’ notice address as set
forth in Section 14.9 is hereby amended in part as follows:

IntraBiotics
Pharmaceuticals, Inc.

2021 Stierlin Court

Mountain View, CA  94043

Attention:  Chief Executive Officer

Telephone:  (650) 526-6800

Telecopy:  (650) 969-0663

9.          Except as otherwise amended herein,
the Agreement shall remain in full force and effect.

	10.	This Amendment may be signed by
  facsimile and in one or more counterparts, each of which shall be deemed an
  original, and all of which together shall constitute a single instrument.

This
Amendment shall be effective as of June 1, 2001.

	Sincerely,	Acknowledged and Agreed:
	 	 
	/s/ Kenneth J. Kelley	/s/ Claudio Quarta
	

	

	Kenneth
  J. Kelley	Claudio
  Quarta
	IntraBiotics Pharmaceuticals, Inc.	Biosearch Italia, S.p.A.
	 	 
	 	May 28, 2001	 	May 28, 2001
	

	 	

	Date	Date
					

 

             Attachment A

             Ramoplanin VRE Program Budget

Analysis

(from BI perspective of IBPI proposed aggreement)

             [*]

[ * ] = Certain confidential information contained in
this document, marked by brackets, has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.Prepared by MerrillDirect

Exhibit 10.24

FIRST AMENDMENT

TO THE AGREEMENT

BETWEEN

INTRABIOTICS PHARMACEUTICALS,
INC.

AND

ALBANY MOLECULAR RESEARCH, INC.

FIRST AMENDMENT

TO THE RESEARCH AND TECHNOLOGY AGREEMENT

BETWEEN

INTRABIOTICS PHARMACEUTICALS, INC.

AND

NEW CHEMICAL ENTITIES, INC.

             THIS FIRST AMENDMENT TO THE RESEARCH AND TECHNOLOGY
AGREEMENT is entered into as of the 13th day of April, 2001, (“Amendment Effective
Date”) by and among INTRABIOTICS PHARMACEUTICALS, INC., a Delaware corporation (“INTRABIOTICS”) and ALBANY
MOLECULAR RESEARCH, a Delaware corporation (“AMRI”).

             RECITALS

             WHEREAS, INTRABIOTICS
and New Chemical Entities, Inc. (NCE) entered into a Research and Technology
Agreement dated January 24, 2001 (the “Original Agreement”) for the screening
of NCE’s proprietary natural product libraries by INTRABIOTICS and its
contractors;

             WHEREAS, AMRI acquired NCE subsequent to the execution of
the Original Agreement and is the successor in interest to NCE with respect to
the Original Agreement;

             WHEREAS, to carry out certain parts of the Research Program,
INTRABIOTICS intends to enter into a Screening Agreement with Cetek Corporation
(“Cetek”) pursuant to which Cetek will utilize Cetek technology to screen the
Screening Libraries licensed by AMRI to INTRABIOTICS; and

             WHEREAS, INTRABIOTICS and AMRI desire to amend and clarify
their respective rights under the Agreement to provide, among other things,
that Cetek will own the Cetek Technology.

             NOW, THEREFORE, in consideration of the foregoing and the covenants
and promises contained in this Amendment, INTRABIOTICS and AMRI hereby amend
the Agreement as follows:

             1.          Unless
otherwise expressly provided herein, defined terms used in this First Amendment
shall have the same meaning as set forth in the Original Agreement, and all
terms herein shall be incorporated into the Original Agreement.  From and after the Amendment Effective Date,
all reference to the “Research and Technology Agreement” in all other documents
delivered in connection with the Research and Technology Agreement shall refer
to the Research and Technology Agreement, as amended hereby.

             2.          All
references to “New Chemical Entities” shall be replaced with “Albany Molecular
Research” and all references to “NCE” shall be replaced with “AMRI”.

             3.          Section 1.14 shall be amended to read as follows:

1.14       "AMRI Research Program
Technology" means all information, know-how, trade secrets, inventions and
data that are made during the course of the parties’ performance under the
Research Program that are not Exclusive Research Program Technology, Cetek
Technology or Other Technology.

             4.          A new Section 1.33 shall be inserted
as follows:

1.33       “Other Technology” means all information,
know-how, trade secrets, inventions and data that are made or discovered during
the course of the INTRABIOTICS’ performance under the Research Program, whether
performed by INTRABIOTICS or a contractor of INTRABIOTICS set forth in Appendix
C other than Cetek, which relate to the screening, isolation or ranking of
compounds that associate with proteins or macromolecular targets, including,
but not limited to any screening assay, the Targets and any data relating
thereto. Other Technology shall not include: the Cetek Technology, the
Screening Libraries, and  Structure Technology.

5.          A new Section 1.34 shall be inserted
as follows:

1.34       “Cetek Technology” means all know-how,
trade secrets, inventions, data, processes, procedures, devices, methods,
formulas, reagents and protocols and other information, including improvements
thereon, whether or not patentable, now or hereafter owned or controlled by
Cetek or developed or discovered by Cetek in the course of screening the
Screening Libraries, for the screening or isolation or ranking of compounds
that associate with proteins or macromolecular targets, including, but not
limited to, any capillary electrophoresis assay. Cetek Technology shall not
include:  (1) the Screening Libraries
and any data relating thereto, (2) the Targets and any data relating thereto,
(3) Screening Data, and (4) the Structure Technology.

             6.          Section 6.1 shall be amended to read
as follows:

6.1       Inventorship of any inventions arising
out of the Research Program shall be determined according to U.S. patent
law.  AMRI shall own all right, title
and interest in the AMRI Research Program Patents, Exclusive Research Program
Patents, Exclusive Research Program Technology, AMRI Research Program
Technology and Structure Technology in each case, regardless of
inventorship.  INTRABIOTICS shall own
all Other Technology and all intellectual property rights related thereto and
all Screening Data.  Cetek shall own all
Cetek Technology.

7.          Section 6.2 shall be amended to read
as follows:

6.2       Each party shall continue to own all
intellectual property owned by such party prior to the Effective Date.  Such intellectual property shall be referred
to herein as such party’s “Background Technology”.

8.          A new
Section 6.9 shall be added as follows:

6.9       The parties acknowledge and agree that
each of them is conducting research and development of its respective
Background Technology on an ongoing basis. 
In the event that any resulting improvements to such Background
Technology or other resulting inventions or developments include know-how,
trade secrets, inventions, data, processes, procedures, devices, methods,
formulas, reagents, protocols and other information which (i) are already known
or in a party’s possession, other than under an obligation of confidentiality
to the other party, or (ii) are developed independently by an employee of a
party without benefit of the other party’s confidential information or
technology, or (iii) become generally available to the public other than as a
result of a disclosure by a party or such party’s directors, officers,
employees, agents or advisors, or (iv) become available to a party on a
non-confidential basis from a source other than the other party or its
advisors, provided that such source is not known by the receiving party to be
bound by a confidentiality agreement with or other obligation of secrecy to the
other party or another party (“Intellectual Property”), ownership of such
Intellectual Property shall be determined according to applicable law.  As used in this Section 6.9 the term “party”
shall mean a party to this agreement and its sublicensees.

             9.          A
new Section 1.35 shall be added as follows:

1.35       “Structure Technology” shall mean any
inventions or discoveries made by Cetek in the course of screening the
Screening Libraries which relate specifically to the making, using or
composition of a particular Active Structure, Target or Sample and have little
or no utility for natural product extracts and protein or macromolecular
targets generally.

10.        Section 2.6 shall be amended to read as
follows:

In the event that
INTRABIOTICS desires to isolate and/or identify the chemical structure of a
compound within a Screening Library, INTRABIOTICS agrees, except to the extent
permitted under Section 2.5, that it will not attempt to perform such
separation and/or identification itself, and will not request any person or
entity other than AMRI to perform such separation or identification.  In the event that INTRABIOTICS is unable to
transfer or cause to be transferred to AMRI a bio-assay to guide fractionation
and dereplication experiments, INTRABIOTICS may request that Cetek perform
fractionation to separate or identify the active fractions and Cetek may
perform such fractionation only as permitted under this Section 2.6.  Upon the request of the RMC, Cetek will
supply such fractionated material to AMRI for dereplication studies.  Using the fractionated material, Cetek may
perform studies to evaluate reversibility of binding.

11.        Section 1.30 shall be amended to read as follows:

1.30        “Target” means INTRABIOTICS’ targets of
interest as listed in Appendix B, as may be amended from time to time by
INTRABIOTICS during the Research Program. 
A Target may be proprietary to third parties other than those
consultants of INTRABIOTICS listed in Appendix C, or in the public domain.

12.        Except as otherwise amended herein, the
Agreement shall remain in full force and effect.

             13.        This First Amendment may be executed in
counterparts and by facsimile.

This
Amendment shall be effective as of the date first written above.

             IN WITNESS WHEREOF, the parties hereto have duly executed this
Amendment.

	INTRABIOTICS PHARMACEUTICALS, INC.	ALBANY MOLECULAR RESEARCH, INC.
	 	 	 	 
	By:	/s/ 
  Kenneth J. Kelley	By:	/s/ 
  Donald E. Kuhla
	 	

	 	

	Title:	President and Chief Executive Officer	Title:	President and Chief Operating Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}]]